At Patents you can conduct a Patent Search, File a Patent Application, find a Patent Attorney, or search available technology through our Patent Exchange. Patents are available using simple keyword or date criteria. If you are looking to hire a patent attorney, you've come to the right place. Protect your idea and hire a patent lawyer.
Patent # | Description |
---|---|
US-9,382,257 |
Substituted pyrrolo[2,3-b]pyrazines as serine/threonine kinase inhibitors Compounds having the formula I wherein R.sup.1 and R.sup.2 are as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for... |
US-9,382,256 |
Formulation of Syk inhibitors Disclosed are pharmaceutical compositions comprising a compound having the formula: ##STR00001## or a pharmaceutically acceptable salt thereof, or a hydrate... |
US-9,382,255 |
Substituted pyrrolopyrimidinylamino-benzothiazolones as MKNK kinase
inhibitors The present invention relates to substituted pyrrolopyrimidinylamino-benzothiazolone compounds of general formula I as described and defined herein, to methods... |
US-9,382,254 |
Compounds and pharmaceutical compositions thereof for the treatment of
cystic fibrosis The present invention discloses compounds according to Formula I: ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, L, and the subscript m are as defined herein.... |
US-9,382,253 |
Metal complexes The present invention relates to metal complexes which contain polymerizable groups and to the polymers obtained using these metal complexes and to electronic... |
US-9,382,252 |
Use of pteridine derivatives for the treatment of increased intracranial
pressure, secondary ischemia, and... The present invention relates to the use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders... |
US-9,382,251 |
Compositions comprising folic acid derivatives, their preparations and
methods of use Described herein are methods for making folic acid derivatives, intermediates, pharmaceutical compositions and uses thereof. |
US-9,382,250 |
Method for producing complex crystal and method for screening complex
crystal The present invention relates to a method for producing a complex crystal composed of two or more different compounds, comprising crystallizing the two or more... |
US-9,382,249 |
Antitumor aza-benzo [f] azulen derivative, method for preparing same, and
use thereof The present invention relates to the field of pharmaceutical chemistry, and particularly to an aza-benzo[f]azulen derivative (I) and an antitumor effect... |
US-9,382,248 |
Mnk inhibitors and methods related thereto The present invention relates to compounds according to Formula (I): ##STR00001## or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof,... |
US-9,382,247 |
Salts and pharmaceutical compositions thereof for the treatment of
inflammatory disorders The present invention discloses salts of a Compound 1: ##STR00001## useful in the prophylaxis and/or treatment of inflammatory conditions, autoimmune diseases,... |
US-9,382,246 |
Inhibitors of Bruton's tyrosine kinase Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the... |
US-9,382,245 |
Compounds and methods for treating HIV infections The present invention is directed to novel nanomolar and picomolar inhibitors of HIV reverse transcriptase, pharmaceutical compositions therefrom and methods... |
US-9,382,244 |
7-azaindole-2,7-naphthyridine derivative for the treatment of tumours The compound 4-(2-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2,7-naphthyridin-1-ylamine and pharmaceutically usable salts and/or tautomers thereof. The use of this ... |
US-9,382,243 |
Azabenzimidazole tetrahydropyran derivatives Novel compounds of the structural formula (I) are activators of AMP-protein kinase and may be useful in the treatment, prevention and suppression of diseases... |
US-9,382,242 |
Preparation and use of compounds as protease inhibitors Disclosed are compounds of the formula I ##STR00001## or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Q is a... |
US-9,382,241 |
Aminoquinazoline and pyridopyrimidine derivatives The invention provides novel compounds having the general formula: ##STR00001## wherein A, R.sup.1, R.sup.2 and R.sup.3 are as defined herein, compositions... |
US-9,382,240 |
Crystalline salts of a potent HCV inhibitor This invention relates to novel tris(hydroxymethyl)aminomethane, choline and N-methyl-D-glucamine salt forms of the following Compound (1) and methods for the... |
US-9,382,239 |
Inhibitors of c-Jun-N-terminal kinase (JNK) The present invention provides novel compounds according to Formula (I): where Ring A, Ring B, X, L.sub.1, L.sub.2, R.sup.A, R.sup.C, R.sup.D, R.sup.E, m, n,... |
US-9,382,238 |
Pyridine derivatives as rearranged during transfection (RET) kinase
inhibitors This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing... |
US-9,382,237 |
3,5-diaminopyrazole kinase inhibitors Provided herein are 3,5-diaminopyrazoles, for example, compounds of Formula IA, that are useful for modulating regulated-in-COPD kinase activity, and... |
US-9,382,236 |
P2X4 receptor antagonist The present invention relates to a diazepine derivative represented by the following general formula (I) (in the formula, R.sup.1 and R.sup.2 represent hydrogen... |
US-9,382,235 |
Unsolvated crystalline form 1 of N-[5-(3,
... The present invention relates to a process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H ... |
US-9,382,234 |
Enhancer of Zeste Homolog 2 inhibitors This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions... |
US-9,382,233 |
Forms of vilazodone and processes for the preparation thereof Vilazodone hydrochloride benzyl alcohol solvates are provided as well as processes for the preparation thereof. |
US-9,382,232 |
Quinoline and cinnoline derivatives and their applications The present invention relates to a series of quinoline and cinnoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or... |
US-9,382,231 |
Bipyrazole derivatives as JAK inhibitors The present invention provides compounds of Formula I: ##STR00001## or pharmaceutically acceptable salts thereof, as well as their compositions and methods of... |
US-9,382,230 |
Methods and compositions for modulating Ire1, SRC and ABL activity Disclosed herein are, inter alia, compositions for modulating Ire1, Src, or Abl, methods for identifying modulating activity in test compounds, and methods for... |
US-9,382,229 |
Compounds and methods of use thereof for treating neurodegenerative
disorders Compounds, compositions, kits and methods for treating conditions related to neurodegeneration or ocular disease, are disclosed. |
US-9,382,228 |
N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and
anti-proliferative activities Described are compounds of Formula I ##STR00001## which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through... |
US-9,382,227 |
Phenylethanolamine-based NMDA receptor antagonists Described herein are enhanced N-methyl-D-aspartate (NMDA) receptor antagonists, pharmaceutical compositions thereof, and their methods of use and treatment,... |
US-9,382,226 |
Aldosterone synthase inhibitors The invention involves compounds of structural Formula (I) and the pharmaceutically acceptable salts thereof. The compounds of the invention are effective at... |
US-9,382,225 |
Reduction of C--O bonds by catalytic transfer hydrogenolysis The present invention relates to a method of reducing a C--O bond to the corresponding C--H bond in a substrate which could be a benzylic alcohol, allylic... |
US-9,382,224 |
7-acyloxychromen-4-one derivatives and the use thereof as self-tanning
substances The present invention relates to chromen-4-one derivatives of the formula (I), to the use thereof as self-tanning substance or for increasing melanin synthesis,... |
US-9,382,223 |
Process for preparation of dronedarone by oxidation of a hydroxyl group The invention relates to a novel process for the preparation of dronedarone (I) and pharmaceutically acceptable salts thereof (formula I), which comprises... |
US-9,382,222 |
Benzyl sulfonamide derivatives as RORc modulators Compounds of the formula Ia or Ib: ##STR00001## or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Y,... |
US-9,382,221 |
Compounds, compositions, and methods for treating alzheimer's disease Novel methods and compounds for treating Alzheimer's Disease are provided. In one aspect, the invention provides methods for treating Alzheimer's Disease by... |
US-9,382,220 |
Methods of synthesis and/or purification of diaminophenothiazinium
compounds Described are methods of synthesis and/or purification of certain 3,7-diamino-phenothiazin-5-ium compounds (referred to herein as "diaminophenothiazinium... |
US-9,382,219 |
Cyclic protein tyrosine kinase inhibitors Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein... |
US-9,382,218 |
N-heteroaryl substituted aniline derivatives as HCV-antivirals The present invention discloses compounds of Formula (I): wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical... |
US-9,382,217 |
Modulators of sphingosine phosphate receptors Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in... |
US-9,382,216 |
Substituted morpholines as modulators for the calcium sensing receptor Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes... |
US-9,382,215 |
Therapeutic methods and agents for treating myotonic dystrophy The invention provides compounds, compositions and methods for treating myotonic dystrophy. The compounds can selectively bind to CUG repeats in RNA, or to CTG... |
US-9,382,214 |
Processes for the preparation of uracil derivatives The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and... |
US-9,382,213 |
Heterocyclic and cyclic analogs of propargyl-linked inhibitors of
dihydrofolate reductase Compounds of Formula I and Formula IA are inhibitors of dihydrofolate reductase and are suitable for use in compositions and methods for dihydrofolate reductase... |
US-9,382,212 |
Preparation of and formulation comprising a MEK inhibitor The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-car- boxylic acid... |
US-9,382,211 |
Stabilized multi-functional antioxidant compounds and methods of use Disclosed are novel stable compounds having anti-oxidant properties and methods of using the compounds for the treatment of diseases or injuries associated with... |
US-9,382,210 |
Articles and methods comprising persistent carbenes and related
compositions Articles and methods comprising persistent carbenes are provided, as well as related compositions. In some embodiments, a persistent carbene may be associated... |
US-9,382,209 |
Polymorphic forms of ivabradine hydrochloride Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed. |
US-9,382,208 |
Negative allosteric modulators of metabotropic glutamate receptor 2 Described are negative allosteric modulators of metabotropic glutamate receptor 2 (mGlu.sub.2), pharmaceutical compositions including the compounds, and methods... |